Dark

Check out our API

APTX
APTINYX INC
stock OTC

Inactive

Dec 29, 2023

0.0960USD+3.170%(+0.0030)231,126

Pre-market

Dec 31, 1969

0.00USD-100.000%(-0.09)0

After-hours

Dec 31, 1969

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 6, 2022

07:37AM EST Aptinyx Highlights Key Goals and Anticipated Development Milestones for 2022 Business Wire

Dec 20, 2021

07:47AM EST Aptinyx to Host Virtual Portfolio Review Event on February 9th, 2022 Business Wire

04:48AM EST SVB Leerink Maintains Outperform on Aptinyx, Lowers Price Target to $10 Benzinga

Dec 16, 2021

07:43AM EST Aptinyx Initiates Phase 2b Study Of NYX-783 In Patients With Post-Traumatic Stress Disorder RTTNews

Dec 13, 2021

07:49AM EST Aptinyx to Present at the 40th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 9, 2021

09:55PM EST Mid-Afternoon Market Update: Nasdaq Falls Over 1%; Reata Pharmaceuticals Shares Plummet Benzinga

09:46PM EST The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO Benzinga

Dec 7, 2021

08:26AM EST The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Dar Benzinga

Nov 18, 2021

07:49AM EST Aptinyx to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference Business Wire

Nov 9, 2021

05:43PM EST Aptinyx Q3 EPS $(0.31), Inline Benzinga

04:06PM EST Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights Business Wire

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

Oct 27, 2021

06:50AM EDT Aptinyx Closes Enrollment In Phase 2b Study Of NYX-2925 In Painful Diabetic Peripheral Neuropathy RTTNews

06:49AM EDT Aptinyx Announced it Completed Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy Benzinga

06:47AM EDT Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy Business Wire

Oct 25, 2021

07:32AM EDT Aptinyx to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021 Business Wire

Oct 20, 2021

08:00AM EDT Aptinyx Appoints Gilmore O'Neill To Board RTTNews

07:57AM EDT Aptinyx Appoints Gilmore O'Neill, M.B., M.M.Sc., to Board of Directors Business Wire

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Sep 20, 2021

07:57AM EDT Aptinyx to Participate in 2021 Cantor Virtual Global Healthcare Conference Business Wire

Sep 16, 2021

06:53AM EDT Aptinyx Reports Secured $50M Growth Capital Credit Facility From K2 HealthVentures Benzinga

06:40AM EDT Aptinyx Secures $50 Mln Growth Capital Credit Facility From K2 HealthVentures RTTNews

06:37AM EDT Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures Business Wire

Aug 31, 2021

07:57AM EDT Aptinyx to Participate in H.C. Wainwright 23rd Annual Global Investment Conference Business Wire

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 10, 2021

05:49PM EDT CORRECTING and REPLACING Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights Business Wire

04:29PM EDT Aptinyx Q2 EPS $(0.29) Misses $(0.25) Estimate Benzinga

04:10PM EDT Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights Business Wire

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

04:05AM EDT Earnings Scheduled For August 10, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 3, 2021

07:57AM EDT Aptinyx to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference Business Wire

Jul 26, 2021

07:57AM EDT Aptinyx to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021 Business Wire

Jul 12, 2021

07:57AM EDT Aptinyx to Participate in William Blair Biotech Focus Conference 2021 Business Wire

Jul 6, 2021

07:57AM EDT Aptinyx To Participate In Cowen Psychedelics & Novel Mechanisms In Neuropsychiatry Summit Jul. 13 Benzinga

07:57AM EDT Aptinyx to Participate in Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit Business Wire

Jun 17, 2021

07:57AM EDT Aptinyx to Participate in Upcoming Investor Conferences Business Wire

Jun 16, 2021

08:20AM EDT The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO Benzinga

06:45AM EDT Aptinyx Provides Updates On Mid-Stage NYX-783 Program In PTSD Patients Benzinga

Jun 15, 2021

04:33PM EDT UPDATE: Aptinyx Says Co. Providing Updated Statistical Analysis For Exploratory Phase 2 Study, Which Has No Impact On Study Conclusions Benzinga

04:33PM EDT UPDATE: Aptinyx Says Identified Statistical Error Made By Contract Research Organization That Performed Statistical Analysis Of Previously-Completed Exploratory Phase 2 Study In Post-Traumatic Stress Disorder Benzinga

04:10PM EDT Aptinyx Says Finalized Design For Phase 2b Program, Says Remains On Track To Commence Q4'21 Benzinga

04:10PM EDT Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder Business Wire

Jun 11, 2021

12:02PM EDT Mid-Day Market Update: Markets Mixed; Novan Shares Spike Higher Benzinga

Jun 8, 2021

01:27PM EDT Aptinyx Granted U.S. Patent Titled 'Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof' Benzinga

Jun 2, 2021

09:27AM EDT Apex Technology Acquisition Corp., AvePoint Announce Registration Statement Effectiveness, June 30, 2021 Scheduled Special Meeting To Approve Business Combination Benzinga

May 13, 2021

04:58PM EDT Aptinyx Q1 EPS $(0.22), Inline, Sales $1.00M Up From $818.00K YoY Benzinga

04:06PM EDT Aptinyx Reports First Quarter 2021 Financial Results and Highlights Business Wire

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

04:15AM EDT Earnings Scheduled For May 13, 2021 Benzinga

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

May 10, 2021

07:57AM EDT Aptinyx Appoints Joan W. Miller, M.D. to Board of Directors Business Wire

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 6, 2021

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

May 5, 2021

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

May 4, 2021

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

Apr 29, 2021

04:05PM EDT Aptinyx to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021 Business Wire

07:15AM EDT Aptinyx To Present Additional Positive Data From Phase 2 Exploratory Study Of NYX-783 In PTSD At Society Of Biological Psychiatry Annual Meeting Benzinga

Apr 27, 2021

07:57AM EDT Aptinyx to Participate in Upcoming Conferences Business Wire

Apr 24, 2021

09:24AM EDT The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx Benzinga

Apr 6, 2021

08:05AM EDT The Daily Biotech Pulse: Illumina Lights Up, Cara Soars On Index Inclusion, Novavax Starts Crossover Vaccine Study, Turning Point Data Readout Benzinga

07:34AM EDT Aptinyx Stock Is Trading Higher After Restarting NYX-458 Study In Dementia Associated Cognitive Impairment Benzinga

06:42AM EDT Aptinyx Recommences Phase 2 Study Of NYX-458; Sees Data From This Study In H2 Of 2022 RTTNews

06:38AM EDT Aptinyx Recommences Phase 2 Study Of NYX-458 In Patients With Cognitive Impairment Associated With Parkinson's Disease Dementia And Dementia With Lewy Bodies; Note: Screening Was Previously Temporarily Suspended Due To COVID-19 Benzinga

06:37AM EDT Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson's Disease Dementia and Dementia with Lewy Bodies Business Wire

Mar 30, 2021

05:24AM EDT Aptinyx Awarded U.S. Patent 10,961,189 'Spiro-lactam NMDA receptor modulators and uses thereof' Benzinga

Mar 24, 2021

05:45PM EDT Aptinyx: Q4 Earnings Insights Benzinga

04:13PM EDT Aptinyx Q4 EPS $(0.20) Beats $(0.24) Estimate Benzinga

04:05PM EDT Aptinyx Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Business Wire

08:59AM EDT The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping Benzinga

04:29AM EDT Earnings Scheduled For March 24, 2021 Benzinga

Mar 2, 2021

08:31AM EST Aptinyx to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 24, 2021 Business Wire

Feb 22, 2021

08:30AM EST Aptinyx to Participate in Upcoming Investor Conferences Business Wire

Feb 16, 2021

05:19AM EST Aptinyx Awarded U.S. Patent 10,918,637 'Spiro-lactam NMDA receptor modulators and uses thereof' Benzinga

05:19AM EST Aptinyx Awarded U.S. Patent 'Spiro-lactam NMDA receptor modulators and uses thereof' Benzinga

Feb 11, 2021

08:30AM EST Aptinyx to Participate at 10th Annual SVB Leerink Global Healthcare Conference Business Wire

Jan 29, 2021

10:31AM EST Return On Capital Employed Overview: Aptinyx Benzinga

10:04AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 29, 2021 Benzinga

08:20AM EST JP Morgan Downgrades Aptinyx to Underweight Benzinga

Jan 19, 2021

08:44AM EST Aptinyx Publishes Review Article In Medicine In Drug Discovery Featuring Data On Novel NMDA Receptor Modulator, NYX-2925 RTTNews

08:38AM EST Aptinyx Highlights Publication Of Review Article Highlighting Preclinical Data In Medicine In Drug Discovery Demonstrating Potential Of NYX-2925 To Treat Chronic, Centralized Pain Conditions Benzinga

08:32AM EST Aptinyx Announces Publication of Review Article Highlighting Preclinical Data in Medicine in Drug Discovery Demonstrating the Potential of NYX-2925 to Treat Chronic, Centralized Pain Conditions Business Wire

Jan 5, 2021

08:37AM EST Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference Business Wire

Jan 4, 2021

08:00AM EST Aptinyx Announces Recommenced Patient Recruitment And Screening In Phase 2 Study Of NYX-2925 RTTNews

07:58AM EST Aptinyx Announces Recommencement Of Phase 2 Study Of NYX-2925 In Patients With Painful Diabetic Peripheral Neuropathy Benzinga

Dec 21, 2020

08:30AM EST Aptinyx to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 16, 2020

08:38AM EST Aptinyx Appoints Andy Kidd President And COO, Effective December 14 RTTNews

08:35AM EST Aptinyx Appoints Andy Kidd, M.D., President And Chief Operating Officer Benzinga

Nov 19, 2020

06:15AM EST HC Wainwright & Co. Maintains Buy on Aptinyx, Raises Price Target to $8 Benzinga

Nov 13, 2020

05:02AM EST SVB Leerink Maintains Outperform on Aptinyx, Lowers Price Target to $12 Benzinga

Nov 12, 2020

04:04PM EST Aptinyx Q3 EPS $(0.24) Beats $(0.29) Estimate, Sales $257.00K Miss $410.00K Estimate Benzinga

04:03PM EST Aptinyx Reports Third Quarter 2020 Financial Results and Recent Highlights Business Wire

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

04:18AM EST Earnings Scheduled For November 12, 2020 Benzinga

Nov 10, 2020

08:37AM EST Aptinyx to Participate in Upcoming Virtual Investor Conferences Business Wire

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Oct 29, 2020

08:37AM EDT Aptinyx to Report Third Quarter Financial Results on Thursday, November 12, 2020 Business Wire

Oct 28, 2020

08:27AM EDT Aptinyx Director Adam Koppel Reported After the Close Tuesday Purchase of 3,333,333 Shares @ Avg Price: $3.00 Benzinga

07:43AM EDT Cantor Fitzgerald Maintains Overweight on Aptinyx, Raises Price Target to $12 Benzinga

Oct 27, 2020

01:44PM EDT Aptinyx shares are trading higher after Piper Sandler initiated coverage on the company's stock with an Overweight rating and announced a $10 price target. Benzinga

01:35PM EDT Piper Sandler Initiates Coverage On Aptinyx On PTSD Candidate Benzinga

10:35AM EDT Benzinga's Top Upgrades, Downgrades For October 27, 2020 Benzinga

05:37AM EDT Piper Sandler Initiates Coverage On Aptinyx with Overweight Rating, Announces Price Target of $10 Benzinga

Oct 26, 2020

04:01PM EDT Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option Business Wire

Oct 22, 2020

11:12AM EDT Mid-Morning Market Update: Markets Edge Lower; Coca-Cola Earnings Top Views Benzinga

Oct 21, 2020

11:06PM EDT Aptinyx Prices Public Offering Of 14 Mln Shares At $3.00/shr RTTNews

10:59PM EDT Aptinyx Announces Pricing of Public Offering of Common Stock Business Wire

08:04AM EDT The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings Benzinga

Oct 20, 2020

04:03PM EDT Aptinyx Announces Proposed Public Offering Of 12M Shares Of Common Stock Benzinga

04:01PM EDT Aptinyx Announces Proposed Public Offering of Common Stock Business Wire

02:34PM EDT Mid-Afternoon Market Update: Dow Rises 1%; Aptinyx Shares Spike Higher Benzinga

12:12PM EDT Mid-Day Market Update: Cleveland BioLabs Jumps On Merger News; Isoray Shares Slide Benzinga

11:18AM EDT Why Aptinyx's Stock Is Trading Higher Today Benzinga

10:23AM EDT Shares of Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company, are surging almost 55 percent or $2.00 in Tuesday's morning trade at $5.66, after touching a new 52-week high of $6.47. RTTNews

08:17AM EDT The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger Benzinga

Oct 19, 2020

05:48PM EDT After-Hours Market: Crown Holdings, Aptinyx, Cleveland RTTNews

04:46PM EDT UPDATE: Aptinyx Says Data Supports Discussion With FDA, Advancement Into Pivotal Study Benzinga

04:45PM EDT UPDATE: Aptinyx Says 'Clinically meaningful and statistically significant improvement on CAPS-5 Arousal and Reactivity Score observed with NYX-783,' 'Clinically meaningful improvement from baseline on CAPS-5 Total Score observed in 50 mg dose arm' Benzinga

04:45PM EDT Aptinyx Reports Top-Line Data From Phase 2 Study Of NYX-783 In Patients With Post-Traumatic Stress Disorder: 'Observed safety and tolerability similar to placebo' Benzinga

04:44PM EDT Aptinyx Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress Disorder Business Wire

Sep 28, 2020

08:29AM EDT Aptinyx Recommences Patient Recruitment In Phase 2 Study Of NYX-2925 In Patients With Fibromyalgia RTTNews

Sep 3, 2020

08:37AM EDT Aptinyx to Present at Upcoming Virtual Investor Conferences Business Wire

Aug 13, 2020

04:12PM EDT Aptinyx Q2 EPS $(0.27) Beats $(0.28) Estimate, Sales $490.00K Down From $925.00K YoY Benzinga

04:05PM EDT Aptinyx Reports Second Quarter 2020 Financial Results and Highlights Business Wire

08:18AM EDT The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller Benzinga

04:03AM EDT Earnings Scheduled For August 13, 2020 Benzinga

Aug 6, 2020

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

07:19AM EDT Biocryst Pharmaceuticals Q2 EPS $(0.24) Beats $(0.25) Estimate Benzinga

Aug 4, 2020

08:37AM EDT Aptinyx to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference Business Wire

Jul 30, 2020

04:01PM EDT Aptinyx to Report Second Quarter Financial Results on Thursday, August 13, 2020 Business Wire

Share